Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study

Gustavsson, Anders ; Raket, Lars Lau LU ; Lilja, Mathias ; Rutten-Jacobs, Loes ; Fues Wahl, Hanna ; Bagijn, Marloes ; Stomrud, Erik LU ; Hansson, Oskar LU orcid and Palmqvist, Sebastian LU orcid (2021) In Alzheimer's and Dementia 17(11). p.1832-1842
Abstract

Quality of life and health utility are important outcomes for patients with Alzheimer's disease (AD) and central for demonstrating the value of new treatments. Estimates in biomarker-confirmed AD populations are missing, potentially delaying payer approval of treatment. We examined whether health utility, assessed with the EuroQoL-5 3-level version (EQ-5D-3L), differed between individuals with a positive or negative amyloid beta (Aβ) biomarker in patients with mild cognitive impairment (MCI) and cognitively unimpaired (CU) participants from the Swedish BioFINDER study (n = 578). Participants with prodromal AD (Aβ-positive MCI) reported better health utility (n = 79, mean = 0.81, 95% confidence interval [CI] 0.77–0.85) than Aβ-negative... (More)

Quality of life and health utility are important outcomes for patients with Alzheimer's disease (AD) and central for demonstrating the value of new treatments. Estimates in biomarker-confirmed AD populations are missing, potentially delaying payer approval of treatment. We examined whether health utility, assessed with the EuroQoL-5 3-level version (EQ-5D-3L), differed between individuals with a positive or negative amyloid beta (Aβ) biomarker in patients with mild cognitive impairment (MCI) and cognitively unimpaired (CU) participants from the Swedish BioFINDER study (n = 578). Participants with prodromal AD (Aβ-positive MCI) reported better health utility (n = 79, mean = 0.81, 95% confidence interval [CI] 0.77–0.85) than Aβ-negative MCI (mean = 0.71, 95% CI 0.64–0.78), but worse than controls (Aβ-negative CU, mean = 0.87, 95% CI 0.86–0.89). Health utility in preclinical AD (Aβ-positive CU; mean = 0.86, 95% CI 0.83–0.89) was similar to controls. This relatively good health utility in prodromal AD suggests a larger value of delaying progression to dementia than previously anticipated and a great value of delaying clinical progression in preclinical AD.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, health utility, modeling, outcomes, quality of life
in
Alzheimer's and Dementia
volume
17
issue
11
pages
1832 - 1842
publisher
Wiley
external identifiers
  • pmid:33984179
  • scopus:85105618597
ISSN
1552-5260
DOI
10.1002/alz.12355
language
English
LU publication?
yes
id
cad4b8e0-a20d-4b38-963e-55655525024e
date added to LUP
2021-06-01 16:19:55
date last changed
2022-08-04 17:20:56
@article{cad4b8e0-a20d-4b38-963e-55655525024e,
  abstract     = {{<p>Quality of life and health utility are important outcomes for patients with Alzheimer's disease (AD) and central for demonstrating the value of new treatments. Estimates in biomarker-confirmed AD populations are missing, potentially delaying payer approval of treatment. We examined whether health utility, assessed with the EuroQoL-5 3-level version (EQ-5D-3L), differed between individuals with a positive or negative amyloid beta (Aβ) biomarker in patients with mild cognitive impairment (MCI) and cognitively unimpaired (CU) participants from the Swedish BioFINDER study (n = 578). Participants with prodromal AD (Aβ-positive MCI) reported better health utility (n = 79, mean = 0.81, 95% confidence interval [CI] 0.77–0.85) than Aβ-negative MCI (mean = 0.71, 95% CI 0.64–0.78), but worse than controls (Aβ-negative CU, mean = 0.87, 95% CI 0.86–0.89). Health utility in preclinical AD (Aβ-positive CU; mean = 0.86, 95% CI 0.83–0.89) was similar to controls. This relatively good health utility in prodromal AD suggests a larger value of delaying progression to dementia than previously anticipated and a great value of delaying clinical progression in preclinical AD.</p>}},
  author       = {{Gustavsson, Anders and Raket, Lars Lau and Lilja, Mathias and Rutten-Jacobs, Loes and Fues Wahl, Hanna and Bagijn, Marloes and Stomrud, Erik and Hansson, Oskar and Palmqvist, Sebastian}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; health utility; modeling; outcomes; quality of life}},
  language     = {{eng}},
  month        = {{05}},
  number       = {{11}},
  pages        = {{1832--1842}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study}},
  url          = {{http://dx.doi.org/10.1002/alz.12355}},
  doi          = {{10.1002/alz.12355}},
  volume       = {{17}},
  year         = {{2021}},
}